{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:42:02Z","timestamp":1793997722821,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Public Health Agency of Canada Internal Funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of antibody-based therapies for the treatment of high consequence viral pathogens has gained interest over the last fifteen years. Here, we sought to evaluate the use of unique camelid-based IgG antibodies to prevent lethal hantavirus pulmonary syndrome (HPS) in Syrian hamsters. Using purified, polyclonal IgG antibodies generated in DNA-immunized alpacas, we demonstrate that post-exposure treatments reduced viral burdens and organ-specific pathology associated with lethal HPS. Antibody treated animals did not exhibit signs of disease and were completely protected. The unique structures and properties, particularly the reduced size, distinct paratope formation and increased solubility of camelid antibodies, in combination with this study support further pre-clinical evaluation of heavy-chain only antibodies for treatment of severe respiratory diseases, including HPS.<\/jats:p>","DOI":"10.1038\/s41598-021-96884-6","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:03:02Z","timestamp":1630404182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Polyclonal alpaca antibodies protect against hantavirus pulmonary syndrome in a lethal Syrian hamster model"],"prefix":"10.1038","volume":"11","author":[{"given":"Patrycja","family":"Sroga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce M.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyne","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvon","family":"Deschambault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Banadyga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Falzarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Safronetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"96884_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pathogens9090775","volume":"9","author":"E Kabwe","year":"2020","unstructured":"Kabwe, E. et al. Orthohantaviruses, emerging zoonotic pathogens. Pathogens 9, 1\u201321 (2020).","journal-title":"Pathogens"},{"key":"96884_CR2","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00705-019-04253-6","volume":"164","author":"A Abudurexiti","year":"2019","unstructured":"Abudurexiti, A. et al. Taxonomy of the order Bunyavirales: Update 2019. Arch. Virol. 164, 1949\u20131965 (2019).","journal-title":"Arch. Virol."},{"key":"96884_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1128\/CMR.00062-09","volume":"23","author":"CB Jonsson","year":"2010","unstructured":"Jonsson, C. B., Figueiredo, L. T. M. & Vapalahti, O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin. Microbiol. Rev. 23, 412\u2013441 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"96884_CR4","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1111\/1469-0691.12291","volume":"21","author":"T Av\u0161i\u010d-\u017dupanc","year":"2019","unstructured":"Av\u0161i\u010d-\u017dupanc, T., Saksida, A. & Korva, M. Hantavirus infections. Clin. Microbiol. Infect. 21, e6\u2013e16 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"96884_CR5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/v11070610","volume":"11","author":"RL Brocato","year":"2019","unstructured":"Brocato, R. L. & Hooper, J. W. Progress on the prevention and treatment of hantavirus disease. Viruses 11, 610 (2019).","journal-title":"Viruses"},{"key":"96884_CR6","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.3389\/fmicb.2019.02989","volume":"10","author":"R Liu","year":"2020","unstructured":"Liu, R. et al. Vaccines and therapeutics against hantaviruses. Front. Microbiol. 10, 2989 (2020).","journal-title":"Front. Microbiol."},{"key":"96884_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJM199404073301401","volume":"330","author":"JS Duchin","year":"1994","unstructured":"Duchin, J. S. et al. Hantavirus Pulmonary syndrome: A clinical description of 17 patients with a newly recognized disease. N. Engl. J. Med. 330, 949\u2013955 (1994).","journal-title":"N. Engl. J. Med."},{"key":"96884_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.antiviral.2012.06.002","volume":"95","author":"D Safronetz","year":"2012","unstructured":"Safronetz, D., Ebihara, H., Feldmann, H. & Hooper, J. W. The Syrian hamster model of hantavirus pulmonary syndrome. Antiviral Res. 95, 282\u2013292 (2012).","journal-title":"Antiviral Res."},{"key":"96884_CR9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1086\/425007","volume":"39","author":"G Mertz","year":"2004","unstructured":"Mertz, G., Miedzinski, L., Goade, D., Pavia, A. & Hjelle, B. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 39, 1307\u20131313 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"96884_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/135965359900400404","volume":"4","author":"L Chapman","year":"1999","unstructured":"Chapman, L., Mertz, G., Peters, C., Jolson, H. & Khan, A. Intravenous ribavirin for hantavirus pulmonary syndrome: Safety and tolerance during 1 year of open-label experience Ribavirin study group. Antivir. Ther. 4, 211\u2013219 (1999).","journal-title":"Antivir. Ther."},{"key":"96884_CR11","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2174\/1389201020666190809112704","volume":"20","author":"M Dibo","year":"2019","unstructured":"Dibo, M. et al. Antibody therapy for the control of viral diseases: An update. Curr. Pharm. Biotechnol. 20, 1108\u20131121 (2019).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"96884_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1517\/14728214.12.4.525","volume":"12","author":"J Ter Meulen","year":"2007","unstructured":"Ter Meulen, J. Monoclonal antibodies for prophylaxis and therapy of infectious diseases. Expert Opin. Emerg. Drugs 12, 525\u2013540 (2007).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"96884_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1086\/315657","volume":"182","author":"M Bharadwaj","year":"2000","unstructured":"Bharadwaj, M., Nofchissey, R., Goade, D., Koster, F. & Hjelle, B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J. Infect. Dis. 182, 43\u201348 (2000).","journal-title":"J. Infect. Dis."},{"key":"96884_CR14","doi-asserted-by":"publisher","first-page":"e0003803","DOI":"10.1371\/journal.pntd.0003803","volume":"9","author":"N Haese","year":"2015","unstructured":"Haese, N. et al. Antiviral biologic produced in DNA vaccine\/goose platform protects hamsters against hantavirus pulmonary syndrome when administered post-exposure. PLoS Negl. Trop. Dis. 9, e0003803 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"96884_CR15","doi-asserted-by":"publisher","first-page":"e35996","DOI":"10.1371\/journal.pone.0035996","volume":"7","author":"R Brocato","year":"2012","unstructured":"Brocato, R., Josleyn, M., Ballantyne, J., Vial, P. & Hooper, J. W. DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). PLoS ONE 7, e35996 (2012).","journal-title":"PLoS ONE"},{"key":"96884_CR16","doi-asserted-by":"publisher","first-page":"264ra162","DOI":"10.1126\/scitranslmed.3010082","volume":"6","author":"JW Hooper","year":"2014","unstructured":"Hooper, J. W. et al. DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci. Transl. Med. 6, 264ra162 (2014).","journal-title":"Sci. Transl. Med."},{"key":"96884_CR17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3389\/fmicb.2020.00832","volume":"11","author":"CC Perley","year":"2020","unstructured":"Perley, C. C. et al. Anti-HFRS human IgG produced in transchromosomic bovines has potent hantavirus neutralizing activity and is protective in animal models. Front. Microbiol. 11, 832 (2020).","journal-title":"Front. Microbiol."},{"key":"96884_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/21645515.2018.1514224","volume":"15","author":"AT Abbas","year":"2019","unstructured":"Abbas, A. T., El-Kafrawy, S. A., Sohrab, S. S. & Azhar, E. I. A. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections. Hum. Vaccin. Immunother. 15, 264\u2013275 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"96884_CR19","doi-asserted-by":"publisher","first-page":"e0130699","DOI":"10.1371\/journal.pone.0130699","volume":"10","author":"H Matsushita","year":"2015","unstructured":"Matsushita, H. et al. Species-specific chromosome engineering greatly improves fully human polyclonal antibody production profile in cattle. PLoS ONE 10, e0130699 (2015).","journal-title":"PLoS ONE"},{"key":"96884_CR20","doi-asserted-by":"publisher","first-page":"e00028-20","DOI":"10.1128\/mBio.00028-20","volume":"11","author":"J Duehr","year":"2020","unstructured":"Duehr, J. et al. Neutralizing monoclonal antibodies against the Gn and the Gc of the andes virus glycoprotein spike complex protect from virus challenge in a preclinical hamster model. MBio 11, e00028-20 (2020).","journal-title":"MBio"},{"key":"96884_CR21","doi-asserted-by":"crossref","unstructured":"Garrido, J. L. et al. Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo. Sci. Transl. Med. 10, (2018).","DOI":"10.1126\/scitranslmed.aat6420"},{"key":"96884_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","volume":"77","author":"MM Harmsen","year":"2007","unstructured":"Harmsen, M. M. & De Haard, H. J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77, 13\u201322 (2007).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"96884_CR23","doi-asserted-by":"crossref","unstructured":"Saerens, D. & Muyldermans, S. Overview of Single Domain Antibodies. in Single Domain Antibodies Methods and Protocols 1\u2013573 (2012).","DOI":"10.1007\/978-1-61779-968-6"},{"key":"96884_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.vetimm.2008.10.299","volume":"128","author":"S Muyldermans","year":"2009","unstructured":"Muyldermans, S. et al. Camelid immunoglobulins and nanobody technology. Vet. Immunol. Immunopathol. 128, 178\u2013183 (2009).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"96884_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: Natural single-domain antibodies. Annu. Rev. Biochem. 82, 775\u2013797 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"96884_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446\u2013448 (1993).","journal-title":"Nature"},{"key":"96884_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.toxicon.2018.03.004","volume":"146","author":"AH Laustsen","year":"2018","unstructured":"Laustsen, A. H. et al. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon 146, 151\u2013175 (2018).","journal-title":"Toxicon"},{"key":"96884_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jim.2007.04.008","volume":"324","author":"DR Maass","year":"2007","unstructured":"Maass, D. R., Sepulveda, J., Pernthaner, A. & Shoemaker, C. B. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J. Immunol. Methods 324, 13\u201325 (2007).","journal-title":"J. Immunol. Methods"},{"key":"96884_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1128\/CVI.00421-09","volume":"17","author":"LP Daley","year":"2010","unstructured":"Daley, L. P. et al. Effector functions of camelid heavy-chain antibodies in immunity to West Nile virus. Clin. Vaccine Immunol. 17, 239\u2013246 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"96884_CR30","doi-asserted-by":"crossref","unstructured":"Raj, V. S. et al. Chimeric camel\/human heavy-chain antibodies protect against MERS-CoV infection. Sci. Adv. 4, eaas9667 (2018).","DOI":"10.1126\/sciadv.aas9667"},{"key":"96884_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","volume":"362","author":"NS Laursen","year":"2018","unstructured":"Laursen, N. S. et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science (80-.) 362, 598\u2013602 (2018).","journal-title":"Science (80-.)"},{"key":"96884_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3851\/IMP2875","volume":"20","author":"PA Vial","year":"2015","unstructured":"Vial, P. A. et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir. Ther. 20, 377\u2013386 (2015).","journal-title":"Antivir. Ther."},{"key":"96884_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.antiviral.2010.05.012","volume":"87","author":"B Thys","year":"2010","unstructured":"Thys, B. et al. In vitro antiviral activity of single domain antibody fragments against poliovirus. Antivir. Res. 87, 257\u2013264 (2010).","journal-title":"Antivir. Res."},{"key":"96884_CR34","doi-asserted-by":"publisher","first-page":"e95263","DOI":"10.1371\/journal.pone.0095263","volume":"9","author":"A Fatima","year":"2014","unstructured":"Fatima, A. et al. Development of VHH antibodies against dengue virus type 2 NS1 and comparison with monoclonal antibodies for use in immunological diagnosis. PLoS ONE 9, e95263 (2014).","journal-title":"PLoS ONE"},{"key":"96884_CR35","doi-asserted-by":"publisher","first-page":"20565","DOI":"10.1073\/pnas.1012865107","volume":"107","author":"S J\u00e4hnichen","year":"2010","unstructured":"J\u00e4hnichen, S. et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc. Natl. Acad. Sci. U. S. A. 107, 20565\u201320570 (2010).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"96884_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","volume":"60","author":"L Detalle","year":"2016","unstructured":"Detalle, L. et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob. Agents Chemother. 60, 6\u201313 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"96884_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/CMR.00010-16","volume":"30","author":"C Griffiths","year":"2017","unstructured":"Griffiths, C., Drews, S. J. & Marchant, D. J. Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment. Clin. Microbiol. Rev. 30, 277\u2013319 (2017).","journal-title":"Clin. Microbiol. Rev."},{"key":"96884_CR38","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/infdis\/jir622","volume":"204","author":"B Schepens","year":"2011","unstructured":"Schepens, B. et al. Nanobodies\u00ae specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J. Infect. Dis. 204, 1692\u20131701 (2011).","journal-title":"J. Infect. Dis."},{"key":"96884_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1006\/viro.2001.1133","volume":"289","author":"JW Hooper","year":"2001","unstructured":"Hooper, J. W., Larsen, T., Custer, D. M. & Schmaljohn, C. S. A lethal disease model for hantavirus pulmonary syndrome. Virology 289, 6\u201314 (2001).","journal-title":"Virology"},{"key":"96884_CR40","doi-asserted-by":"publisher","first-page":"e1002426","DOI":"10.1371\/journal.ppat.1002426","volume":"7","author":"D Safronetz","year":"2011","unstructured":"Safronetz, D. et al. Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus. PLoS Pathog. 7, e1002426 (2011).","journal-title":"PLoS Pathog."},{"key":"96884_CR41","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1128\/JVI.00373-09","volume":"83","author":"D Safronetz","year":"2009","unstructured":"Safronetz, D. et al. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J. Virol. 83, 7285\u20137295 (2009).","journal-title":"J. Virol."},{"key":"96884_CR42","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.3390\/ijms19113605","volume":"19","author":"D Hobernik","year":"2018","unstructured":"Hobernik, D. & Bros, M. DNA vaccines-how far from clinical use?. Int. J. Mol. Sci. 19, 3605 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"96884_CR43","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/nmeth.3170","volume":"11","author":"PC Fridy","year":"2014","unstructured":"Fridy, P. C. et al. A robust pipeline for rapid production of versatile nanobody repertoires. Nat. Methods 11, 1253\u20131260 (2014).","journal-title":"Nat. Methods"},{"key":"96884_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/biol-2016-0001","volume":"11","author":"M Haddad","year":"2016","unstructured":"Haddad, M., Soukkarieh, C., Khalaf, H. E. & Abbady, A. Q. Purification of polyclonal IgG specific for Camelid\u2019s antibodies and their recombinant nanobodies. Open Life Sci. 11, 1\u20139 (2016).","journal-title":"Open Life Sci."},{"key":"96884_CR45","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0168-1702(02)00129-6","volume":"89","author":"JD Meissner","year":"2002","unstructured":"Meissner, J. D., Rowe, J. E., Borucki, M. K. & St. Jeor, S. C. Complete nucleotide sequence of a Chilean hantavirus. Virus Res. 89, 131\u2013143 (2002).","journal-title":"Virus Res."},{"key":"96884_CR46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3201\/eid0404.980425","volume":"4","author":"J Toro","year":"1998","unstructured":"Toro, J. et al. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg. Infect. Dis. 4, 687\u2013694 (1998).","journal-title":"Emerg. Infect. Dis."},{"key":"96884_CR47","doi-asserted-by":"publisher","first-page":"e00108-21","DOI":"10.1128\/JVI.00108-21","volume":"95","author":"BM Warner","year":"2021","unstructured":"Warner, B. M. et al. Differential pathogenesis between andes virus strains CHI-7913 and Chile-9717869 in Syrian hamsters. J. Virol. 95, e00108-21 (2021).","journal-title":"J. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96884-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96884-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96884-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:17:41Z","timestamp":1670080661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96884-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["96884"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-96884-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17440"}}